…FOR TREATMENT AND RESEARCH IN MS (ECTRIMS), GOTHENBURG, SWEDEN, OCTOBER 13-16, 2010 – The oral agent fingolimod consistently reduces relapse rates regardless of disease severity or treatment history, and drug discontinuation is not associated with significant clinical complications, according to new studies and analyses presented at ECTRIMS. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email addres…

…FOR TREATMENT AND RESEARCH IN MS (ECTRIMS), GOTHENBURG, SWEDEN, OCTOBER 13-16, 2010 – Patients with clinically isolated syndrome (CIS) suggestive of MS treated with an immunomodulatory therapy are at high risk of stopping treatment once they experience a relapse, according to an analysis of data from the MSBase Incident Study (MSBASIS) (Spelman et al. ECTRIMS 2010; abstract P819). Subscribe to read more It takes 30 seconds or login using your ema…

…in RRMS) was a phase III trial comparing fingolimod and intramuscular beta-interferon-1a in patients with relapsing-remitting MS (Cohen et al. N Engl J Med 2010; 362: 402-415; updated results in Clinical Developments in Multiple Sclerosis , Neurosens, July 7, 2010). The 12-month study reported annualized relapse rates (ARR) of 0.16 with fingolimod 0.5 mg/day, 0.20 with fingolimod 1.25 mg/day and 0.33 with beta-interferon-1a. Subscribe to read mor…

…FOR TREATMENT AND RESEARCH IN MS (ECTRIMS), GOTHENBURG, SWEDEN, OCTOBER 13-16, 2010 – An analysis of data from a longitudinal cohort of MS patients diagnosed in Gothenburg, Sweden (n=307), in the period 1950-1964 reports that 18% have remained non-progressive 45 years after disease onset (Andersen O. ECTRIMS 2010; abstract 36). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you reg…